MorphoSys AG (MPSYF)
USD 73.27
(0.0%)
USD 73.27
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -252.47 Million EUR | -255.6% |
| 2022 | 162.26 Million EUR | 158.45% |
| 2021 | -277.6 Million EUR | -332.48% |
| 2020 | 119.4 Million EUR | 213.59% |
| 2019 | -105.12 Million EUR | -75.47% |
| 2018 | -59.9 Million EUR | 10.66% |
| 2017 | -67.05 Million EUR | -14.15% |
| 2016 | -58.74 Million EUR | -401.63% |
| 2015 | 19.47 Million EUR | 494.98% |
| 2014 | -4.93 Million EUR | -146.15% |
| 2013 | 10.68 Million EUR | 312.01% |
| 2012 | 2.59 Million EUR | -77.37% |
| 2011 | 11.45 Million EUR | 16.33% |
| 2010 | 9.84 Million EUR | -13.62% |
| 2009 | 11.4 Million EUR | -30.57% |
| 2008 | 16.42 Million EUR | 134.02% |
| 2007 | 7.01 Million EUR | 13.64% |
| 2006 | 6.17 Million EUR | 0.25% |
| 2005 | 6.16 Million EUR | 860.44% |
| 2004 | 641.4 Thousand EUR | 118.51% |
| 2003 | -3.46 Million EUR | 86.42% |
| 2002 | -25.51 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -264.42 Million EUR | -224.94% |
| 2023 Q1 | -69.5 Million EUR | -70.81% |
| 2023 Q4 | -81.37 Million EUR | -59.56% |
| 2023 Q3 | -51 Million EUR | -0.9% |
| 2023 FY | -252.47 Million EUR | -255.6% |
| 2023 Q2 | -50.54 Million EUR | 27.28% |
| 2022 Q3 | -29.9 Million EUR | 45.74% |
| 2022 Q4 | -40.68 Million EUR | -36.09% |
| 2022 Q1 | -67.9 Million EUR | 79.11% |
| 2022 FY | 162.26 Million EUR | 158.45% |
| 2022 Q2 | -55.1 Million EUR | 18.84% |
| 2021 Q2 | -71.4 Million EUR | -149.66% |
| 2021 FY | -277.6 Million EUR | -332.48% |
| 2021 Q3 | -82.35 Million EUR | -15.35% |
| 2021 Q1 | -28.59 Million EUR | 61.95% |
| 2021 Q4 | -325 Million EUR | -294.61% |
| 2020 Q1 | 203.51 Million EUR | 499.54% |
| 2020 Q4 | -75.16 Million EUR | -21.18% |
| 2020 Q3 | -62.03 Million EUR | -28.25% |
| 2020 FY | 119.4 Million EUR | 213.59% |
| 2020 Q2 | -48.36 Million EUR | -123.77% |
| 2019 Q4 | -50.93 Million EUR | -82.9% |
| 2019 Q1 | -23.7 Million EUR | 48.36% |
| 2019 Q2 | -5.6 Million EUR | 76.37% |
| 2019 FY | -105.12 Million EUR | -75.47% |
| 2019 Q3 | -27.85 Million EUR | -397.13% |
| 2018 Q1 | -19.08 Million EUR | -47.98% |
| 2018 Q4 | -45.91 Million EUR | -254.57% |
| 2018 Q2 | -24.61 Million EUR | -28.93% |
| 2018 FY | -59.9 Million EUR | 10.66% |
| 2018 Q3 | 29.7 Million EUR | 220.69% |
| 2017 Q1 | -15.04 Million EUR | 45.03% |
| 2017 FY | -67.05 Million EUR | -14.15% |
| 2017 Q4 | -12.89 Million EUR | 44.34% |
| 2017 Q3 | -23.17 Million EUR | -47.57% |
| 2017 Q2 | -15.7 Million EUR | -4.39% |
| 2016 Q2 | -9.52 Million EUR | 2.47% |
| 2016 FY | -58.74 Million EUR | -401.63% |
| 2016 Q4 | -27.36 Million EUR | -108.98% |
| 2016 Q3 | -13.09 Million EUR | -37.5% |
| 2016 Q1 | -9.76 Million EUR | 43.97% |
| 2015 Q4 | -17.42 Million EUR | -52.6% |
| 2015 FY | 19.47 Million EUR | 494.98% |
| 2015 Q3 | -11.42 Million EUR | -3.41% |
| 2015 Q2 | -11.04 Million EUR | -120.94% |
| 2015 Q1 | 52.74 Million EUR | 3359.11% |
| 2014 Q1 | 1.35 Million EUR | 131.39% |
| 2014 FY | -4.93 Million EUR | -146.15% |
| 2014 Q4 | -1.61 Million EUR | 64.78% |
| 2014 Q3 | -4.59 Million EUR | -389.64% |
| 2014 Q2 | -938.49 Thousand EUR | -169.49% |
| 2013 Q4 | -4.3 Million EUR | -64.55% |
| 2013 Q2 | 14.71 Million EUR | 526.25% |
| 2013 FY | 10.68 Million EUR | 312.01% |
| 2013 Q1 | 2.34 Million EUR | -51.83% |
| 2013 Q3 | -2.61 Million EUR | -117.77% |
| 2012 Q1 | -803.62 Thousand EUR | 89.66% |
| 2012 Q2 | -1.14 Million EUR | -42.32% |
| 2012 Q3 | -418.51 Thousand EUR | 63.41% |
| 2012 Q4 | 4.87 Million EUR | 1265.44% |
| 2012 FY | 2.59 Million EUR | -77.37% |
| 2011 Q1 | 28.84 Million EUR | 1422.78% |
| 2011 FY | 11.45 Million EUR | 16.33% |
| 2011 Q2 | -5.53 Million EUR | -119.19% |
| 2011 Q4 | -7.77 Million EUR | -130.32% |
| 2011 Q3 | -3.37 Million EUR | 39.03% |
| 2010 Q4 | 1.89 Million EUR | 640.42% |
| 2010 FY | 9.84 Million EUR | -13.62% |
| 2010 Q1 | 4.66 Million EUR | 124.67% |
| 2010 Q2 | 3.64 Million EUR | -21.9% |
| 2010 Q3 | -350.49 Thousand EUR | -109.62% |
| 2009 Q3 | 2.71 Million EUR | 13.44% |
| 2009 Q4 | 2.07 Million EUR | -23.55% |
| 2009 FY | 11.4 Million EUR | -30.57% |
| 2009 Q2 | 2.39 Million EUR | -43.26% |
| 2009 Q1 | 4.21 Million EUR | 0.0% |
| 2008 FY | 16.42 Million EUR | 134.02% |
| 2007 FY | 7.01 Million EUR | 13.64% |
| 2006 FY | 6.17 Million EUR | 0.25% |
| 2005 FY | 6.16 Million EUR | 860.44% |
| 2004 FY | 641.4 Thousand EUR | 118.51% |
| 2003 FY | -3.46 Million EUR | 86.42% |
| 2002 FY | -25.51 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -17908.375% |
| CSL Limited | 3.7 Billion USD | 106.82% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -251.706% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 5237.04% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -96365.694% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -1314.668% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 408.454% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -16336.702% |
| Mesoblast Limited | -84.14 Million USD | -200.041% |
| Marizyme, Inc. | -34.08 Million USD | -640.691% |
| Genus plc | 6.4 Million USD | 4044.934% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 2691.5% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -27007.711% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -2923.662% |
| ContraFect Corporation | -56.88 Million USD | -343.804% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -5443.161% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -38.67 Million USD | -552.873% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -9078.138% |
| MultiCell Technologies, Inc. | -722.81 USD | -34929660.518% |
| Accustem Sciences Inc. | -3.74 Million USD | -6639.123% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -327.998% |
| EV Biologics, Inc. | -483.06 Thousand USD | -52165.714% |
| Q BioMed Inc. | -3.44 Million USD | -7227.45% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 7232.085% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -9508.894% |
| Biomind Labs Inc. | -1 Million USD | -24907.434% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -3697.762% |
| Skye Bioscience, Inc. | -13.67 Million USD | -1746.69% |
| SQZ Biotechnologies Company | -75.82 Million USD | -232.972% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -842834.702% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -4904.989% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -8757.224% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -1490.926% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -64708.841% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | -5074.168% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -12609.714% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -12963.981% |
| GB Sciences, Inc. | -1.42 Million USD | -17673.615% |
| Alpha Cognition Inc. | -9.7 Million USD | -2501.341% |
| argenx SE | -425.04 Million USD | 40.601% |
| HST Global, Inc. | -140.9 Thousand USD | -179079.034% |
| Halberd Corporation | -75.05 Thousand USD | -336310.129% |
| Enzolytics Inc. | -2.14 Million USD | -11649.618% |
| Resverlogix Corp. | -12.74 Million USD | -1880.358% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -7868.875% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -354.846% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -359.278% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -24083.506% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -8602.311% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -8548.078% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -13442.151% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -15886.007% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -7314.9% |
| AVAX Technologies, Inc. | 6.69 Million USD | 3872.304% |
| ONE Bio Corp. | 13.68 Million USD | 1945.374% |
| Zenith Capital Corp. | -8.94 Million USD | -2723.167% |
| Genscript Biotech Corporation | -415.79 Million USD | 39.278% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -1449161.248% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -10182.819% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -147108.022% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -12493.836% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -22344.169% |
| Agentix Corp. | -1.37 Million USD | -18305.3% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -3.04 Million USD | -8204.442% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -25556.728% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -20001.577% |
| BioStem Technologies, Inc. | -7.77 Million USD | -3145.62% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -139016.622% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -18805.941% |
| LadRx Corporation | -3.82 Million USD | -6503.046% |
| Cell Source, Inc. | -4.32 Million USD | -5737.124% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -60667.404% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -36653.156% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -36653.156% |
| NovAccess Global Inc. | -2.46 Million USD | -10135.118% |
| Affymax, Inc. | -15.04 Million USD | -1578.026% |
| Itoco Inc. | -919.14 Thousand USD | -27368.699% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -5856.846% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -22462.628% |
| CytoDyn Inc. | -18.05 Million USD | -1298.138% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -1002982.249% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -114621.054% |
| Qrons Inc. | -643.67 Thousand USD | -39123.99% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -44607.901% |
| SYBLEU INC | -149.18 Thousand USD | -169142.393% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -11222.399% |
| Rebus Holdings, Inc. | -664 Thousand USD | -37923.464% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -13800.403% |
| Mobile Lads Corp. | -554.55 Thousand USD | -45428.05% |
| International Stem Cell Corporation | -663 Thousand USD | -37980.815% |
| Bioxytran, Inc. | -3.82 Million USD | -6509.06% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -479527.283% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -1241177.296% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -596.178% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -15504.19% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -34211.47% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -8015.583% |
| Neutra Corp. | -229.48 Thousand USD | -109917.954% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -1339.511% |
| PureTech Health plc | -146.19 Million USD | -72.693% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -1074.791% |
| IXICO plc | -1.43 Million USD | -17469.645% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -2560.16% |
| Gelesis Holdings, Inc. | -121.8 Million USD | -107.277% |
| CSL Limited | 3.81 Billion USD | 106.623% |
| Cellectis S.A. | -108.85 Million USD | -131.933% |